Fezolinetant effective treatment of vasomotor symptoms associated with menopause
A study by Kimball A Johnson and peers found fezolinetant to be a safe and effective treatment for moderate-to-severe vasomotor symptoms (VMS) associated with menopause. The findings were published in The Journal of Clinical Endocrinology & Metabolism.
The clinical trial evaluated the efficacy and safety of fezolinetant, a drug for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. The trial included women between the ages of 40-65 who experienced at least 7 moderate-to-severe VMS per day.
The study was a double-blind, placebo-controlled 12-week trial, followed by a 40-week active treatment extension. Participants were randomized to receive placebo, fezolinetant 30 mg, or fezolinetant 45 mg daily for the initial 12 weeks. After the initial 12 weeks, participants who completed the trial were rerandomized to receive fezolinetant for an additional 40 weeks. The primary endpoints were the mean daily change from baseline in VMS frequency and severity at weeks 4 and 12.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.